Sarika Gupta

Dr. Sarika Gupta


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2023 in Science
Verified
Journal Article
Closed access
PSParminder Singh
Parminder Singh
KGKishore Gollapalli
Kishore Gollapalli
SMStefano Mangiola
Stefano Mangiola
DSDaniela Schranner
Daniela Schranner
MYMohd Aslam Yusuf
Mohd Aslam Yusuf
Vijay YadavVijay Yadav
Vijay Yadav
Aging is associated with changes in circulating levels of various molecules, some of which remain undefined. We find that concentrations of circulating taurine decline with aging in mice, monkeys, and humans. A reversal of this decline through taurine supplementation increased the health span (the period of healthy living) and life span in mice and health span in monkeys. Mechanistically, taurine reduced cellular senescence, protected against telomerase deficiency, suppressed mitochondrial dysfunction, decreased DNA damage, and attenuated inflammaging. In humans, lower taurine concentrations correlated with several age-related diseases and taurine concentrations increased after acute endurance exercise. Thus, taurine deficiency may be a driver of aging because its reversal increases health span in worms, rodents, and primates and life span in worms and rodents. Clinical trials in humans seem warranted to test whether taurine deficiency might drive aging in humans.

18 May 2015 in Scientific Reports
Verified
Journal Article
Open access
NANuzhat Ahsan
Nuzhat Ahsan
SMSatyendra Mishra
Satyendra Mishra
MJManish Kumar Jain
Manish Kumar Jain
ASAvadhesha Surolia
Avadhesha Surolia
SGSarika Gupta
Sarika Gupta
Accumulating evidence suggests that deposition of neurotoxic α-synuclein aggregates in the brain during the development of neurodegenerative diseases like Parkinson’s disease can be curbed by anti-aggregation strategies that either disrupt or eliminate toxic aggregates. Curcumin, a dietary polyphenol exhibits anti-amyloid activity but the use of this polyphenol is limited owing to its instability. As chemical modifications in curcumin confiscate this limitation, such efforts are intensively performed to discover molecules with similar but enhanced stability and superior properties. This study focuses on the inhibitory effect of two stable analogs of curcumin viz. curcumin pyrazole and curcumin isoxazole and their derivatives against α-synuclein aggregation, fibrillization and toxicity. Employing biochemical, biophysical and cell based assays we discovered that curcumin pyrazole (3) and its derivative N-(3-Nitrophenylpyrazole) curcumin (15) exhibit remarkable potency in not only arresting fibrillization and disrupting preformed fibrils but also preventing formation of A11 conformation in the protein that imparts toxic effects. Compounds 3 and 15 also decreased neurotoxicity associated with fast aggregating A53T mutant form of α-synuclein. These two analogues of curcumin described here may therefore be useful therapeutic inhibitors for the treatment of α-synuclein amyloidosis and toxicity in Parkinson’s disease and other synucleinopathies.

10 December 2013 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
VVV Vijayan
V Vijayan
MKM Khandelwal
M Khandelwal
KMK Manglani
K Manglani
SGSarika Gupta
Sarika Gupta
ASAvadhesha Surolia
Avadhesha Surolia

23 September 2022 in Neurobiology of Disease
Verified
Journal Article
Open access
MKMayuri Khandelwal
Mayuri Khandelwal
KMKapil Manglani
Kapil Manglani
Prabhat UpadhyayPrabhat Upadhyay
Prabhat Upadhyay
MAMohammad Azad
Mohammad Azad
SGSarika Gupta
Sarika Gupta
Alzheimer's disease (AD) is a progressive devastating neurodegenerative disorder characterized by extracellular amyloid beta (Aβ42) plaque formation, hyperphosphorylation of tau protein leading to intracellular neurofibrillary tangle formation. Recently discovered hallmark features responsible for AD pathogenesis are neuronal insulin resistance, dysregulation in adiponectin and AMPK signaling. The presence of adiponectin and its receptor in the brain with its unique anti-diabetic effects and association with neurodegenerative diseases has raised our interest in exploring orally active small molecule adiponectin receptor agonist, AdipoRon. To date, all the available drugs for the treatment of AD provides symptomatic relief and do not stall the progression of the disease. Indeed, it is becoming increasingly apparent to find appropriate targets. Here, we attempt to shed lights on adiponectin receptor agonist, AdipoRon and its downstream molecular targets in reducing disease pathogenesis and insulin resistance. In brain, AdipoRon induced AMPK activation, increased insulin sensitivity, reduced amyloid beta plaque deposition and improved cognitive impairment. Levels of BACE were also downregulated while LDLR, APOE and neprilysin were upregulated promoting amyloid beta clearance from brain. AdipoRon further reduced the chronic inflammatory marker, GFAP and improved synaptic markers PSD-95 and synaptophysin in APP/PS1 mice. Our in-vitro studies further confirmed the potential role of AdipoRon in improving insulin sensitivity by increasing GLUT 4 translocation, glucose uptake and insulin signaling under hyperinsulinemic condition. Our findings suggest that AdipoRon could be a promising lead in the future treatment strategies in the development of effective AD treatment.

10 February 2017 in BioFactors
Verified
Journal Article
Closed access
PDF file
TCTandrika Chattopadhyay
Tandrika Chattopadhyay
Rajiv Ranjan SinghRajiv Ranjan Singh
Rajiv Ranjan Singh
SGSarika Gupta
Sarika Gupta
ASAvadhesha Surolia
Avadhesha Surolia

1 December 2019 in Toxicology
Verified
Journal Article
Closed access
JKJasim Khan
Jasim Khan
SSShikha Salhotra
Shikha Salhotra
PGPoonam Goswami
Poonam Goswami
JAJuheb Akhter
Juheb Akhter
SJShagufta Jahan
Shagufta Jahan
SRS Raisuddin
S Raisuddin